Abstract

Bionanocapsules (BNCs) are hollow nanoparticles that are composed of L protein (the hepatitis B virus surface antigen) and show specific affinity for human hepatocytes. The pre-S1 peptide displayed on the surface of BNCs is the specific ligand for binding to the receptor on human hepatocytes. Therefore, BNCs are not delivered to other tissues, such as the brain. The aim of the present study was to develop a novel drug delivery system (DDS) targeting brain tumors using BNCs that selectively targeted brain tumors. Epidermal growth factor receptor (EGFR), especially a constitutively active genomic sequence deletion variant of EGFR (EGFRvIII), is overexpressed in human glioblastoma. In the present study, we replaced the pre-S1 peptide with the antibody affinity motif of protein A and made hybrid BNCs conjugated with anti-human EGFR antibody recognizing EGFRvIII. The hybrid BNCs were efficiently delivered to glioma cells but not normal glial cells. Moreover, we confirmed the specific delivery of the hybrid BNCs to brain tumors in an in vivo brain tumor model. These results suggest that this new approach using BNCs is a promising system for brain tumor-targeted drug delivery.

Original languageEnglish
Pages (from-to)159-164
Number of pages6
JournalJournal of Controlled Release
Volume122
Issue number2
DOIs
Publication statusPublished - Sep 26 2007

Fingerprint

Brain Neoplasms
Epidermal Growth Factor Receptor
Hepatocytes
Peptides
Antibody Affinity
Sequence Deletion
Staphylococcal Protein A
Drug Delivery Systems
Glioblastoma
Hepatitis B Surface Antigens
Glioma
Neuroglia
Nanoparticles
Ligands
Antibodies
Brain
Pharmaceutical Preparations
epidermal growth factor receptor VIII

Keywords

  • Brain tumor
  • Drug delivery system (DDS)
  • Gene therapy
  • Hepatitis virus B (HBV)

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Development of bionanocapsules targeting brain tumors. / Tsutsui, Yumi; Tomizawa, Kazuhito; Nagita, Mana; Michiue, Hiroyuki; Nishiki, Tei-ichi; Ohmori, Iori; Seno, Masaharu; Matsui, Hideki.

In: Journal of Controlled Release, Vol. 122, No. 2, 26.09.2007, p. 159-164.

Research output: Contribution to journalArticle

@article{b5ac79af498c44dbb5e8af667b6bde4b,
title = "Development of bionanocapsules targeting brain tumors",
abstract = "Bionanocapsules (BNCs) are hollow nanoparticles that are composed of L protein (the hepatitis B virus surface antigen) and show specific affinity for human hepatocytes. The pre-S1 peptide displayed on the surface of BNCs is the specific ligand for binding to the receptor on human hepatocytes. Therefore, BNCs are not delivered to other tissues, such as the brain. The aim of the present study was to develop a novel drug delivery system (DDS) targeting brain tumors using BNCs that selectively targeted brain tumors. Epidermal growth factor receptor (EGFR), especially a constitutively active genomic sequence deletion variant of EGFR (EGFRvIII), is overexpressed in human glioblastoma. In the present study, we replaced the pre-S1 peptide with the antibody affinity motif of protein A and made hybrid BNCs conjugated with anti-human EGFR antibody recognizing EGFRvIII. The hybrid BNCs were efficiently delivered to glioma cells but not normal glial cells. Moreover, we confirmed the specific delivery of the hybrid BNCs to brain tumors in an in vivo brain tumor model. These results suggest that this new approach using BNCs is a promising system for brain tumor-targeted drug delivery.",
keywords = "Brain tumor, Drug delivery system (DDS), Gene therapy, Hepatitis virus B (HBV)",
author = "Yumi Tsutsui and Kazuhito Tomizawa and Mana Nagita and Hiroyuki Michiue and Tei-ichi Nishiki and Iori Ohmori and Masaharu Seno and Hideki Matsui",
year = "2007",
month = "9",
day = "26",
doi = "10.1016/j.jconrel.2007.06.019",
language = "English",
volume = "122",
pages = "159--164",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Development of bionanocapsules targeting brain tumors

AU - Tsutsui, Yumi

AU - Tomizawa, Kazuhito

AU - Nagita, Mana

AU - Michiue, Hiroyuki

AU - Nishiki, Tei-ichi

AU - Ohmori, Iori

AU - Seno, Masaharu

AU - Matsui, Hideki

PY - 2007/9/26

Y1 - 2007/9/26

N2 - Bionanocapsules (BNCs) are hollow nanoparticles that are composed of L protein (the hepatitis B virus surface antigen) and show specific affinity for human hepatocytes. The pre-S1 peptide displayed on the surface of BNCs is the specific ligand for binding to the receptor on human hepatocytes. Therefore, BNCs are not delivered to other tissues, such as the brain. The aim of the present study was to develop a novel drug delivery system (DDS) targeting brain tumors using BNCs that selectively targeted brain tumors. Epidermal growth factor receptor (EGFR), especially a constitutively active genomic sequence deletion variant of EGFR (EGFRvIII), is overexpressed in human glioblastoma. In the present study, we replaced the pre-S1 peptide with the antibody affinity motif of protein A and made hybrid BNCs conjugated with anti-human EGFR antibody recognizing EGFRvIII. The hybrid BNCs were efficiently delivered to glioma cells but not normal glial cells. Moreover, we confirmed the specific delivery of the hybrid BNCs to brain tumors in an in vivo brain tumor model. These results suggest that this new approach using BNCs is a promising system for brain tumor-targeted drug delivery.

AB - Bionanocapsules (BNCs) are hollow nanoparticles that are composed of L protein (the hepatitis B virus surface antigen) and show specific affinity for human hepatocytes. The pre-S1 peptide displayed on the surface of BNCs is the specific ligand for binding to the receptor on human hepatocytes. Therefore, BNCs are not delivered to other tissues, such as the brain. The aim of the present study was to develop a novel drug delivery system (DDS) targeting brain tumors using BNCs that selectively targeted brain tumors. Epidermal growth factor receptor (EGFR), especially a constitutively active genomic sequence deletion variant of EGFR (EGFRvIII), is overexpressed in human glioblastoma. In the present study, we replaced the pre-S1 peptide with the antibody affinity motif of protein A and made hybrid BNCs conjugated with anti-human EGFR antibody recognizing EGFRvIII. The hybrid BNCs were efficiently delivered to glioma cells but not normal glial cells. Moreover, we confirmed the specific delivery of the hybrid BNCs to brain tumors in an in vivo brain tumor model. These results suggest that this new approach using BNCs is a promising system for brain tumor-targeted drug delivery.

KW - Brain tumor

KW - Drug delivery system (DDS)

KW - Gene therapy

KW - Hepatitis virus B (HBV)

UR - http://www.scopus.com/inward/record.url?scp=34548402938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548402938&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2007.06.019

DO - 10.1016/j.jconrel.2007.06.019

M3 - Article

VL - 122

SP - 159

EP - 164

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2

ER -